Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974206 | 1.00 | RIPK1 (0.47) | RIPK1LMNAKDM4EL3MBTL1PPARG | |
| SCHEMBL5303572 | 1.00 | RIPK1 (0.47) | RIPK1LMNAKDM4EL3MBTL1PPARG | |
| SCHEMBL27911728 | 0.86 | RIPK1 (0.46) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL3391000 | 0.84 | HRH1 (0.42) | LMNAKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2542325 | 0.82 | LMNA (0.48) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL2541606 | 0.82 | LMNA (0.48) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL5159743 | 0.82 | LMNA (0.48) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL10472662 | 0.81 | RIPK1 (0.46) | RIPK1LMNAKDM4EAOC3ALDH1A1 | |
| SCHEMBL11044391 | 0.79 | MMP13 (0.39) | LMNAKDM4EALDH1A1 | |
| SCHEMBL9291993 | 0.79 | KMT2A (0.45) | RIPK1LMNAKDM4EL3MBTL1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664195-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8080536-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7816345-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20080125605-A1 | Novel Phosphorus-Containing Prodrugs | METABASIS THERAPEUTICS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-7303739-B2 | Prodrugs for liver specific drug delivery | METABASIS THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070249564-A1 | Novel phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1165570-B9 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1724276-A1 | Novel phosphorus-containing prodrugs | Metabasis Therapeutics, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1165570-B1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1634886-A2 | Novel phosphorus-containing prodrug | Metabasis Therapeutics, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050101775-A1 | Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2005-05-12 | — | — | US | disclosed |
| US-6752981-B1 | CYCLIC PHOSPH(ORAMID)ATE PRODRUGS HAVING ALCOHOL, AMINE, ORTHIOL GROUPS ATTACHED TO THE PHOSPHORUS IN THE C3N2P OR C3O2P RING | METABASIS THERAPEUTICS, INC. | 2004-06-22 | — | — | US | disclosed |
| EP-1210354-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | Metabasis Therapeutics, Inc. (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001018013-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | METABASIS THERAPEUTICS, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125605-A1 | Novel Phosphorus-Containing Prodrugs | PYGL, ALPI, SLC10A1 | RIPK1 4557/4885LMNA 3305/4885KDM4E 3564/4885 |
| US-20050101775-A1 | Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging | PYGL, PHOSPHO1, OAT | RIPK1 4800/4885LMNA 3367/4885KDM4E 3585/4885 |
| US-20070249564-A1 | Novel phosphorus-containing prodrugs | PYGL, ALPI, SLC10A1 | RIPK1 4557/4885LMNA 3305/4885KDM4E 3564/4885 |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | RIPK1 4557/4885LMNA 3305/4885KDM4E 3564/4885 |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | RIPK1 4557/4885LMNA 3305/4885KDM4E 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.